食管癌放化疗期间重度淋巴细胞减少的预测列线图
研究基于860例接受放化疗的食管癌患者建立并验证了预测4级淋巴细胞减少的临床列线图,预测因子包括年龄、计划靶区体积与低体重指数的交互作用、光子而非质子治疗及较低基线绝对淋巴细胞计数,内部校正c统计量为0.76,外部验证144例c统计量为0.71,列线图将患者分为4个风险组,预测风险分别为10%、24%、43%和70%。
要点
- 4级淋巴细胞减少定义为放化疗期间绝对淋巴细胞计数最低值<0.2×103/μL。
- 预测因子包括年龄较高、计划靶区体积较大与较低体重指数的交互作用、光子治疗及基线绝对淋巴细胞计数较低。
- 列线图4个风险组的预测风险分别为10%、24%、43%和70%,可用于风险分层。
核心结论
- 建立了放化疗前临床列线图并完成验证,用于预测食管癌放化疗期间4级放射性淋巴细胞减少,可对患者进行风险分层。
研究设计与样本
- 开发集为连续接受食管癌放化疗的患者,验证集来自另一机构的独立患者;采用多变量logistic回归建模,并以bootstrapping进行内部验证、在验证集中进行外部验证。
- 共纳入860例患者,其中322例(37%)发生4级淋巴细胞减少;外部验证集144例,其中58例(40%)发生4级淋巴细胞减少。
主要发现
- 最终模型中年龄较高、计划靶区体积较大与较低体重指数的交互作用、光子而非质子治疗、基线绝对淋巴细胞计数较低为预测因子,校正c统计量为0.76。
- 外部验证的c统计量为0.71。
- 基于列线图的4个风险组预测风险率分别为10%、24%、43%和70%。
关键数值与推荐
- 4级淋巴细胞减少定义为放化疗期间绝对淋巴细胞计数最低值<0.2×103/μL。
- 内部校正c统计量为0.76,外部验证c统计量为0.71。
- 4个风险组的预测风险率分别为10%、24%、43%和70%。
临床怎么用
- 治疗前可用该列线图对食管癌放化疗患者进行4级淋巴细胞减少风险分层,识别适合采取减轻淋巴细胞减少策略或未来治疗方法的个体。
- 模型中光子治疗与质子治疗为不同预测因子,提示放疗技术选择可能影响淋巴细胞减少风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In patients with esophageal cancer, occurrence of severe radiation-induced lymphopenia during chemoradiation therapy has been associated with worse progression-free and overall survival. The aim of this study was to develop and validate a pretreatment clinical nomogram for the prediction of grade 4 lymphopenia. METHODS AND MATERIALS: A development set of consecutive patients who underwent chemoradiation therapy for esophageal cancer and an independent validation set of patients from another institution were identified. Grade 4 lymphopenia was defined as an absolute lymphocyte count nadir during chemoradiation therapy of <0.2 × 103/μL. Multivariable logistic regression analysis was used to create a prediction model for grade 4 lymphopenia in the development set, which was internally validated using bootstrapping and externally validated by applying the model to the validation set. The model was presented as a nomogram yielding 4 risk groups. RESULTS: Among 860 included patients, 322 (37%) experienced grade 4 lymphopenia. Higher age, larger planning target volume in interaction with lower body mass index, photon- rather than proton-based therapy, and lower baseline absolute lymphocyte count were predictive in the final model (corrected c-statistic, 0.76). External validation in 144 patients, among whom 58 (40%) had grade 4 lymphopenia, yielded a c-statistic of 0.71. Four nomogram-based risk groups yielded predicted risk rates of 10%, 24%, 43%, and 70%, respectively. CONCLUSIONS: A pretreatment clinical nomogram was developed and validated for the prediction of grade 4 radiation-induced lymphopenia during chemoradiation therapy for esophageal cancer. The nomogram can risk stratify individual patients suitable for lymphopenia-mitigating strategies or potential future therapeutic approaches to ultimately improve survival.
引用
- van Rossum PSN, Deng W, Routman DM, et al. Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram. Pract Radiat Oncol. 2019. PMID: 31369887. doi:10.1016/j.prro.2019.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。